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The presence of tumor budding (TuB) at the invasive front of rectal cancers is a valuable indicator of tumor aggressiveness. Tumor
buds, typically identified as single cells or small tumor cell clusters detached from the main tumor body, are characterized by loss of
cell adhesion, increased migratory, and invasion potential and have been referred to as malignant stem cells. The adverse clinical
outcome of patients with a high-grade TuB phenotype has consistently been demonstrated. TuB is a category IIB prognostic factor;
it has yet to be investigated in the prospective setting. The value of TuB in oncological and pathological practice goes beyond
its use as a simple histomorphological marker of tumor aggressiveness. In this paper, we outline three situations in which the
assessment of TuB may have direct implications on treatment within the multidisciplinary management of patients with rectal
cancer: (a) patients with TNM stage II (i.e., T3/T4, N0) disease potentially benefitting from adjuvant therapy, (b) patients with
early submucosally invasive (T1, sm1-sm3) carcinomas at a high risk of nodal positivity and (c) the role of intratumoral budding
assessed in preoperative biopsies as a marker for lymph node and distant metastasis thus potentially aiding the identification of
patients suitable for neoadjuvant therapy.
1. Introduction
Tumor budding (TuB) refers to the presence of detached sin-
gle tumor cells or clusters of up to 5 cells scattered within
the stroma at the invasive tumor front of many different
solid cancers [1]. TuB as a histomorphological feature is best
described in gastrointestinal tumors and was first compre-
hensively investigated by Jass in the mid 1980s in patients
with rectal cancer [2]. TuB can be evaluated at high mag-
nification using regular H&E staining but its visualization is
markedly facilitated with the use of pan-cytokeratin stains
(Figure 1).
It is hypothesized that tumor buds, or at least a sub-
population of these cells, have undergone a process similar to
epithelial mesenchymal transition (EMT) and have acquired
the ability to act as malignant stem cells [3]. Immunohisto-
chemical staining of tumor buds in colorectal cancers shows
a clear overexpression of markers involved in extracellular
matrix degradation, angiogenesis, migration, and invasion
and decreased Ki67 staining indicative of a low proliferation
rate [4]. An overexpression of nuclear beta-catenin and
simultaneous loss of cell adhesion markers, in particular, E-
cadherin is classically observed in tumor-budding cells [5].
With such an aggressive phenotypic constellation, it is
not surprising that TuB has consistently been linked to lymph
node positivity, the presence of lymphatic and venous inva-
sion, as well as with the presence of distant metastatic disease
[6–12]. The frequency of high-grade TuB in colon and rectal
cancer varies; it has generally been reported to occur in 25–
60% of all cases but is correlated with disease progression
[7, 9, 13–15]. For example, high-grade TuB is reported in
15–17% of patients with early pT1 tumors [8, 15, 16], 26% of
pT2 cases [17], 36–51% of pT3 tumors [12, 17, 18], and up to
73% of pT4 cancers [18]. In addition, it occurs significantly
more frequently in patients with node-positive tumors (51–
75%) in comparison to patients with TNM (6th ed.) stage IIs
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Figure 1: Immunohistochemical analysis highlighting the presence
of peritumoral buds at the invasion front of rectal cancer (pancy-
tokeratin stain: CK22, 40x magnification).
(T3/T4, N0) (15–29%) cancers [8, 15, 17]. Currently, TuB is
listed as a category IIB prognostic factor and many studies
have confirmed that the presence of TuB is associated with
poorer overall and disease-specific and disease-free survival,
in most cases independently of the TNM stage [19].
The value of TuB in oncological and pathological practice
goes beyond its use as a simple histomorphological marker of
tumor aggressiveness. In this paper, we outline three situa-
tions in which the assessment of TuB may have direct impli-
cations on treatment within the multidisciplinary manage-
ment of patients with rectal cancer. These include (a) the
identification of patients with TNM stage II disease poten-
tially benefitting from adjuvant therapy, (b) the identifica-
tion of patients with early submucosally invasive (T1) carci-
nomas at a high risk of nodal positivity, and (c) the use of
tumor budding as a marker of prognosis and predictor of
local and distant relapse assessable in preoperative biopsies.
1.1. Stage II Rectal Cancer Patients. Stage II colorectal cancer
patients represent a clinically heterogeneous group. Data
from the SEER (1975–2005) Public Use File show 5-year
survival trends for patients with colon and rectal cancer
[35]. In particular for the latter, 5-year overall survival rates
decrease dramatically from 64.5% for IIA (T3N0), to 51.6%
for IIB (T4aN0) and 32.3% for IIC (T4bN0). Generally,
patients with stage II colorectal cancer are not typically con-
sidered for additional adjuvant therapy without the presence
of additional high-risk features such as perforation or venous
and lymphatic invasion [36]. It is suggested, however, that a
subgroup of patients with stage II disease who would other-
wise have unfavorable clinical outcome and high-risk for
metastasis may in fact benefit from adjuvant therapy but the
identification of such patients using histomorphological or
molecular markers is unclear [37].
Although the prognostic effect of high-grade TuB has
been well described, studies focusing on the subgroup of
stage II cancers are few. Kevans and colleagues evaluated 258
patients with stage II disease and the correlation of TuB with
survival and with expression of EMT-related protein markers
[38]. They showed that TuB was the only independent mar-
ker of poor outcome and had a major effect on the relative
risk (RR) of death; patients with high-grade TuB were nearly
8 times more likely to die of disease compared to patients
with low-grade TuB. Wang et al. performed a study using
128 patients and evaluated 5-year cancer-specific survival
[12]. They show a significant reduction in survival from 91%
to 63% in patients with low- versus high-grade TuB and a
RR of death of 4.76. Nakamura and colleagues studied 5-
and 10-year survival rates for 200 stage II patients as well as
the association of TuB on the presence of distant metastasis
[9]. Again a substantial reduction in 5-year (93.9% and
73.9%) and 10-year (90.6% and 67.8%) survival time was
observed in patients with low-grade versus high-grade TuB
tumors. Tanaka and colleagues confirm this finding, report-
ing disease-specific survival rates of 98% versus 74% in
patients with and without TuB, respectively, [10]. Moreover,
TuB in stage II patients has been shown to be independent of
other prognostic features [13, 39]. An increased frequency of
liver and peritoneal metastasis was noted in the high-grade
TuB group [9]. Earlier studies show that the sensitivity and
specificity of high-grade TuB for distant metastatic disease in
patients with stage II tumors are 0.76 and 0.739, respectively,
[14]. Frequencies of local recurrence are significantly higher
in patients with high- versus low-grade TuB (48% versus
4.5%, resp.) [10]. Finally, the presence of TuB has been sig-
nificantly associated with isolated tumor cells in lymph nodes
of patients with stage II disease in both univariate and
multivariate analysis [40].
Taken together, these results strongly suggest that TuB in
patients with stage II colorectal cancers has the potential to
contribute independent prognostic information. It is linked
to more aggressive tumor behavior and is associated with
local and distant metastasis. These findings indicate that TuB
should be considered as an important histomorphological
parameter and may be worthy of investigation and inclusion
in prospective clinical trials of patients with stage II disease.
1.2. Tumor Budding in Early Rectal Cancers. An important
issue in the management of patients with submucosally
invasive (T1) colorectal carcinomas is the identification of
patients after endoscopic resection that may be at “high risk”
for lymph node positivity and thus likely to benefit from sur-
gical resection. The rate of lymph node positivity in this
setting is low, approximately 10–15% [23, 24, 27, 29]. Non-
etheless histomorphological features capable of predicting
lymph node involvement are highly sought after.
TuB has been shown in several studies to have predictive
power for lymph node involvement in either univariate or
multivariate analyses (Table 1). In addition to other features
such as histological type, lymphatic and venous invasion,
TuB is significantly more frequent in cases with lymph node
positivity [22, 24–26, 28, 29]. One study evaluated the impact
of TuB in T1 cancers and the potential for the development
of distant metastasis. In one subgroup of T1 patients even-
tually developing metastatic disease and a control group of
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Table 1: Summary of studies evaluating tumor budding in submucosally invasive (T1) colorectal carcinomas.
Ref. Number of patients Endpoint Summary of relevant findings
[20] 499 LN+ 8.2% of T1 were LN+. Several features were independent predictors of LN+: tumor
differentiation/mucinous histology, depth of submucosal invasion, venous invasion, and TuB.
[6] 111 LN+ TuB was associated with LN+ in univariate but not multivariate analysis when analysed with
protein markers.
[21] 32 DM In comparison to a control group, TuB was more frequent in patients who eventually had a
distant metastasis in univariate but not multivariate analysis.
[22] 111 LN+ Several features were evaluated including lymphatic and venous invasion, submucosal depth,
histologic type, and TuB. In multivariate analysis, only histologic type and TuB predicted LN+.
[23] 65 LN+ T1-T2 rectal cancers. 6.9% of T1 were LN+. TuB predicted lateral LN+.
[24] 322 LN+
14.3% of T1 were LN+. Several features predicted LN+: invasion depth, lymphatic and venous
invasion, tumor differentiation, growth pattern, and TuB. Only lymphatic invasion,
differentiation, and TuB were independent predictors in multivariate analysis.
[25] 124 LN+ and DM
Elastica von Gieson, D2-40, and CAM5 were used to enhance visualization of venous invasion,
lymphatic invasion, and TuB, respectively. TuB was an independent predictor of LN+ and
DM+ in multivariate analysis.
[26] 87 LN+ and LR
Prospective study evaluating two groups of patients after endoscopic resection: a surgical
group and a follow-up group without surgery. TuB was the only independent predictor of LN+
in multivariate analysis.
[27] 164 LN+ 9.8% of T1 were LN+. TuB was significantly associated with LN+ in univariate and
multivariate analysis.
[28] 71 LN+
Tumor size, depth of invasion, histologic type, TuB, and lymphatic invasion were predictors in
univariate analysis but only TuB and lymphatic invasion were significant in multivariate
analysis.
[29] 86 LN+ 13% of T1 were LN+. Vascular invasion, tumor budding, and degree of submucosal invasion
could be combined to strongly predict LN+.
[30] 214 LN+ Several histopathological and protein markers were evaluated. TuB was a significant predictor
in univariate and multivariate analysis.
[31] 76 LN+ TuB can be used in a predictive equation for LN+.
[32] 56 LN+ TuB evaluated using CAM5 was significantly more frequent in LN+ (16/42) than LN negative
(0/14) cases.
[16] 159 LN+, OS 10.1% of T1 were LN+ and were associated with several features including TuB. TuB did not
influence overall survival.
[33] 51 LN+, LR TuB was associated to lymphatic invasion, LN+, and local relapse.
[34] 79 LN+ 13.9% were LN+. TuB was one of five risk factors for LN+.
TuB: tumor budding; LN: lymph node; DM: distant metastasis; LR: local recurrence; OS: overall survival.
T1 patients with favorable long-term outcome, TuB was
significantly more frequent in the metastatic cohort [21].
A different study on 145 patients with T1 cancers used
immunohistochemistry and special stains to identify venous
invasion, lymphatic invasion, and the presence of TuB by
Elastica van Gieson, D2-40 and CAM5 staining, respectively,
[25]. In multivariate analysis of lymph node positivity, only
venous invasion and TuB were independently predictive
of involvement. TuB could predict the presence of distant
metastases but only in univariate analysis.
The examples listed in Table 1 underline the potential
importance of the additional assessment of TuB in the patho-
logical diagnosis of early pT1 cancers. TuB assessed in these
submucosally invasive carcinomas during daily routine may
have a promising role as a histomorphological marker for the
prediction of lymph node positivity in this setting.
1.3. Is There a Role for Tumor Budding in the Preoperative
Setting? Traditionally, the preoperative rectal biopsy can
supply three different types of information. The first is the
histopathological diagnosis and confirmation of carcinoma,
the second is the histological subtype, and the third is the
degree of differentiation (tumor grade). However, recently,
studies have not only noted the presence of tumor buds
within the preoperative biopsy specimen but have also
linked this feature to unfavorable prognostic parameters. We
have described the presence of tumor budding within the
biopsy specimen as “intratumoral” budding (ITB) in order
to distinguish it from the classical “peritumoral” budding
(PTB) that is located at the invasive front and thus not nor-
mally evaluable in biopsy specimens [41] (Figure 2).
The first assessment of tumor budding in rectal cancer
biopsies dates to 1989 [42]. Morodomi and colleagues
observed that nearly half of all rectal cancer biopsies con-
tained ITB and its presence was a strong indicator of lymph
node positivity. Specifically, lymph node involvement was
observed in 78.8% of ITB-positive cases and in only 28.1% of
ITB-negative rectal cancers. Despite these promising results,
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Figure 2: Presence of intratumoral buds (arrows) in the main
tumor body of a rectal cancer (pan-cytokeratin stain: CK22, 40x
magnification).
the issue of budding within biopsy specimens was only
addressed once again in 2011. Using two cohorts of colorectal
cancer patients from all stages totaling more than 500 cases,
we could confirm the value of ITB as a predictor of lymph
node positivity with similar sensitivity (72.7%) and speci-
ficity (72.1%) [41]. The presence of ITB not only correlated
with vascular invasion but also showed an independent and
unfavorable prognostic effect in multivariable analysis. A
recent study by Giger et al. evaluated ITB in preoperative
biopsies and the predictive values for both lymph node and
distant metastasis in a series of 72 colorectal cancers of all
TNM stages [43]. Seventeen percent of all cases were found
to have high-grade ITB. Of the ITB positive cases, 83.3% had
lymph node metastasis and 82% had distant metastasis. This
is in contrast to only 51% and 35% of ITB-negative cases,
respectively.
A strong linear correlation between the presence of ITB in
biopsies and corresponding PTB in resection specimens has
been made [41, 43]. This is relevant since the identification
of “invasion front” can in some postoperative specimens be
challenging. A recent meta-analysis of 42 different histo-
morphological and immunohistochemical markers in colon
and rectal cancers aimed to identify predictors of lymph
node metastasis. Focusing on the subset of rectal cancers,
Glasgow and colleagues found only two predictive factors,
one of which was tumor budding at the invasion front. Again,
the sensitivity and specificity of tumor budding for node-
positivity across 7 studies with more than 1500 patients were
70% and 69.4% [44].
Taken together, the current body of evidence indicates
that regardless of its localization, that is, within the main
tumor body or invasion front, tumor budding may be a reli-
able histomorphological predictor of lymph node metastasis
and a factor of poor prognosis which can be applied to both
postoperative specimen and, most importantly, preoperative
biopsy.
2. Conclusion
At least two avenues of investigation should still be clarified
before implementing TuB as a criterion for patient man-
agement. First, no prospective studies have been conducted
to definitely validate the potential of TuB in the clinical
decision-making process. Secondly, TuB remains severely
underreported in daily diagnostic routine due largely to the
absence of a standardized or internationally acceptedmethod
for its assessment. Nonetheless, efforts are currently on-going
to compare and validate the prognostic effects of TuB using
various methods of assessment and in particular their inter-
and intraobserver agreement. The evidence supporting an
important role of TuB in the clinical and multidisciplinary
management of patients with rectal cancer, for example in
the setting of stage II and submucosally invasive tumors
continues to grow. Although less than a handful of studies
have evaluated the presence of intratumoral budding from
the preoperative rectal biopsy, the ability to predict, with
high accuracy, the presence of lymph node metastases in the
pretreatment setting would be of considerable clinical value.
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